Galeazzi Mauro
Galeazzi Mauro
Professore Ordinario di Reumatologia, Università di Siena
Email verificata su unisi.it
TitoloCitata daAnno
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
R Cervera, JC Piette, J Font, MA Khamashta, Y Shoenfeld, MT Camps, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2002
16682002
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 82 (5), 299-308, 2003
12002003
Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 72 (2), 113-124, 1993
10211993
Immunosuppressive therapy in lupus nephritis: the Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide
FA Houssiau, C Vasconcelos, D D'Cruz, GD Sebastiani, ER Garrido, ...
Arthritis & Rheumatism 46 (8), 2121-2131, 2002
9152002
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
R Cervera, MA Khamashta, Y Shoenfeld, MT Camps, S Jacobsen, E Kiss, ...
Annals of the Rheumatic Diseases 68 (9), 1428-1432, 2009
532*2009
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus …
R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ...
Medicine 78 (3), 167-175, 1999
4931999
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
FA Houssiau, C Vasconcelos, D D’Cruz, GD Sebastiani, ...
Annals of the rheumatic diseases 69 (01), 61-64, 2010
3982010
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long‐term followup of patients in the Euro‐Lupus Nephritis Trial
FA Houssiau, C Vasconcelos, D D'cruz, GD Sebastiani, ...
Arthritis & rheumatism 50 (12), 3934-3940, 2004
3602004
Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
R Cervera, JC Piette, J Font, MA Khamashta, Y Shoenfeld, MT Camps, ...
Arthritis Rheum 46 (4), 1019-1027, 2002
2572002
miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis
V Fulci, G Scappucci, GD Sebastiani, C Giannitti, D Franceschini, ...
Human immunology 71 (2), 206-211, 2010
2022010
Accuracy of anti–ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta‐analysis
FB Karassa, A Afeltra, A Ambrozic, DM Chang, F De Keyser, A Doria, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2006
1862006
The antiphospholipid syndrome: a syndrome in evolution.
RA Asherson, R Cervera
Annals of the rheumatic diseases 51 (2), 147, 1992
152*1992
Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed
B Frediani, G Filippou, P Falsetti, S Lorenzini, F Baldi, C Acciai, C Siagkri, ...
Annals of the rheumatic diseases 64 (4), 638-640, 2005
1512005
Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there?
A Fioravanti, L Cantarini, GM Guidelli, M Galeazzi
Rheumatology international 31 (1), 1-8, 2011
1462011
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
L Mancarella, F Bobbio-Pallavicini, F Ceccarelli, PC Falappone, ...
The Journal of Rheumatology 34 (8), 1670-1673, 2007
1462007
Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the “Euro-Lupus Project”
R Cervera
Autoimmunity reviews 5 (3), 180-186, 2006
1352006
Safety of anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection
C Ferri, G Ferraccioli, D Ferrari, M Galeazzi, G Lapadula, C Montecucco, ...
The Journal of Rheumatology 35 (10), 1944-1949, 2008
1312008
Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine
E Gremese, A Carletto, M Padovan, F Atzeni, B Raffeiner, AR Giardina, ...
Arthritis care & research 65 (1), 94-100, 2013
1262013
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the …
F Atzeni, P Sarzi-Puttini, C Botsios, A Carletto, P Cipriani, EG Favalli, ...
Autoimmunity reviews 12 (2), 225-229, 2012
1262012
HCV infection: pathogenesis, clinical manifestations and therapy
A Antonelli, C Ferri, M Galeazzi, C Giannitti, D Manno, G Mieli-Vergani, ...
Clinical and experimental rheumatology 26 (2), S39, 2008
1252008
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20